Showing 654 results

Filters Content type: News, Editors' picks, About HIV Topic: New & experimental hepatitis C treatment

News and information about clinical trials and regulatory approval of new medications to treat hepatitis C.

New & experimental hepatitis C treatment

FDA, academia and industry team up to end hepatitis C

Editor's pick
University of Florida press release
30 August 2013
New & experimental hepatitis C treatment

Medivir announces interim results from Cohort 2 of the COSMOS study evaluating Simeprevir and Sofosbuvir in HCV patients with METAVIR scores F3-F4

Editor's pick
Medivir press release
29 August 2013
New & experimental hepatitis C treatment

Investigational oral regimen for hepatitis C shows promise in NIH trial

Editor's pick
Eurekalert Inf Dis
28 August 2013
New & experimental hepatitis C treatment

Vertex’s VX-135 partial hold signals heightened FDA scrutiny toward HCV drugs

Editor's pick
Financial Times
27 August 2013
New & experimental hepatitis C treatment

Physicians are Foregoing Treatment of Their HCV Patients Until New Agents Become Available

Editor's pick
BioTrends
6 August 2013
Access to healthcare

To End Hepatitis C, Patients Must Come Before Profits

Editor's pick
Huffington Post
30 July 2013
New & experimental hepatitis C treatment

Sign-on letter to Gilead about sofosbuvir

Editor's pick
TRT-5
29 July 2013
New & experimental hepatitis C treatment

Vertex Provides Update on Ongoing All-Oral Studies of VX-135 in Hepatitis C

Editor's pick
Vertex press release
26 July 2013
New & experimental hepatitis C treatment

U.S. FDA puts hold on Vertex hepatitis study

Editor's pick
Reuters
26 July 2013
New & experimental hepatitis C treatment

Are Patients Receiving the Latest Anti-HCV Drugs?

Editor's pick
AGA Journals blog
22 July 2013
New & experimental hepatitis C treatment

How to Save $200 Billion and Cure Hepatitis C

Editor's pick
Xconomy
22 July 2013
New & experimental hepatitis C treatment

TRT-5: Gilead refuses access to treatment to seriously ill hepatitis C patients

Editor's pick
EATG
5 July 2013
New & experimental hepatitis C treatment

AbbVie interferon-free hepatitis C combo works well with reduced ribavirin dose

News
2 July 2013
Access to healthcare

2013 Pipeline Report calls on leaders to get the best HIV, hepatitis C virus (HCV), and tuberculosis drugs, diagnostics, and vaccines to the most people as quickly as possible

Editor's pick
Treatment Action Group
30 June 2013
New & experimental hepatitis C treatment

The beginning of the end of hepatitis C?

News
25 June 2013
New & experimental hepatitis C treatment

AbbVie Says It Can Be First With New Hepatitis C Drugs

Editor's pick
Bloomberg
14 June 2013
New & experimental hepatitis C treatment

FDA Grants Priority Review To Oral Hepatitis C Drug Sofosbuvir, Approval Set For December

Editor's pick
Medical Daily
10 June 2013
New & experimental hepatitis C treatment

Drugs Go From Hit to Dud in Two Years in Hepatitis Race

Editor's pick
Bloomberg
4 June 2013
New & experimental hepatitis C treatment

An all-oral combination phase II study of Simeprevir and Samatasvir (IDX719) for the treatment of hepatitis C virus infection initiated

Editor's pick
Medivir
30 May 2013
New & experimental hepatitis C treatment

Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients

Editor's pick
Janssen press release
22 May 2013
Hepatitis C treatment

Recent Advances in the Treatment of Chronic Hepatitis C Threaten to Leave Some Parts of the World Behind

Editor's pick
Medscape (requires registration)
21 May 2013
New & experimental hepatitis C treatment

U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C

Editor's pick
Janssen press release
13 May 2013
New & experimental hepatitis C treatment

New HCV combinations could have a big role in prevention, but only if treatment rates increase

News
11 May 2013
New & experimental hepatitis C treatment

Gilead Reports Interim Data From Phase 2 LONESTAR Study

Editor's pick
Gilead press release
3 May 2013